Abstract
This research analyzed the results of treatment of 32 patients with ischemic stroke with the drug neurotropin, an antioxidant with antihypoxant properties, evaluated its clinical efficacy, the effect on the processes of protein oxidative modification, and the antioxidant activity of the blood. The control group consisted of 15 people, in whose traditional therapy neurotropin was not included. The study showed that the use of neurotropin in complex therapy contributed to the regression of neurological deficit, caused a positive effect on the oxidative metabolism of the brain, hemostasis, and had a hypolipidemic effect. Thus, the inclusion of neurotrophin in the complex therapy of ischemic strokes is reasonable and expedient.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
